Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma

(2021) Wataru Munakata et al.   CANCER SCIENCE

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

(2020) Mrinal Gounder et al.   LANCET ONCOLOGY

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

(2020) Franck Morschhauser et al.   LANCET ONCOLOGY

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

(2019) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

How I manage patients with follicular lymphoma

(2019) Carla Casulo   BRITISH JOURNAL OF HAEMATOLOGY

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

(2018) Antoine Italiano et al.   LANCET ONCOLOGY

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

(2018) Alfredo Rivas-Delgado et al.   BRITISH JOURNAL OF HAEMATOLOGY

Follicular lymphoma: evolving therapeutic strategies

(2016) B. S. Kahl et al.   BLOOD

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

(2014) I. W. Flinn et al.   BLOOD

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

(2014) S. K. Knutson et al.   MOLECULAR CANCER THERAPEUTICS

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

(2013) S. K. Knutson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

(2010) Ken Ohmachi et al.   CANCER SCIENCE